I like the CEOs quote here. It looks like BMY wont raise their bid.
Thomas Tobin
Managing Director
RESEARCH EDGE, LLC
"Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner"
Will Receive $1 Billion Upon Completion of Transaction
PRINCETON, N.J., Oct 06, 2008 (BUSINESS WIRE) -- Eli Lilly and Company (NYSE: LLY) announced today that it will acquire ImClone Systems (NASDAQ:IMCL) for $70 per share, or approximately $6.5 billion. Bristol-Myers Squibb currently owns approximately 16.6 percent of all outstanding shares of ImClone. Based on Bristol-Myers Squibb's ownership of 14.4 million shares of ImClone, the transaction will be worth approximately $1 billion in cash to Bristol-Myers Squibb.
"We are pleased to have initiated a process that has resulted in the substantial increase of ImClone's value for all of its stockholders," said James M. Cornelius, Chairman and Chief Executive Officer, Bristol-Myers Squibb. "We are also proud to have contributed to this creation of value by providing commercial and R&D support to the company over the course of our relationship, which will continue now with Eli Lilly, a well-respected research organization.
"From the beginning, we had viewed our potential acquisition of ImClone as a strategically and financially sound add-on to our oncology business, consolidating a successful relationship that has extended over seven years. We felt it was in the best interest of Bristol-Myers Squibb shareholders not to raise our previous $62/share all cash offer, exercising discipline and evaluating this potential investment within the context of other alternatives open to the company.
"Looking ahead, we will work closely with Eli Lilly and Company, a company I know well, to continue to bring to patients not only ERBITUX(R), the important cancer therapy we co-commercialize in the U.S. and Canada with ImClone, and co-develop in Japan with Merck KGaA and ImClone, but other compounds, including IMC-11F8, under development by ImClone to which Bristol-Myers Squibb holds long-term marketing rights."
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life.
SOURCE: Bristol-Myers Squibb
Bristol-Myers Squibb
Communications:
Tracy Furey,
Brian Henry,
or
Investor Relations:
John Elicker,
Copyright Business Wire 2008
BRISTOL-MYERS SQUIBB CO COM STK USD0.10
US1101221083
ELI LILLY AND COMPANY COM NPV
US5324571083
IMCLONE SYSTEMS INC COM USD0.001
US45245W1099
Thomas Tobin
Managing Director
RESEARCH EDGE, LLC
"Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner"
Will Receive $1 Billion Upon Completion of Transaction
PRINCETON, N.J., Oct 06, 2008 (BUSINESS WIRE) -- Eli Lilly and Company (NYSE: LLY) announced today that it will acquire ImClone Systems (NASDAQ:IMCL) for $70 per share, or approximately $6.5 billion. Bristol-Myers Squibb currently owns approximately 16.6 percent of all outstanding shares of ImClone. Based on Bristol-Myers Squibb's ownership of 14.4 million shares of ImClone, the transaction will be worth approximately $1 billion in cash to Bristol-Myers Squibb.
"We are pleased to have initiated a process that has resulted in the substantial increase of ImClone's value for all of its stockholders," said James M. Cornelius, Chairman and Chief Executive Officer, Bristol-Myers Squibb. "We are also proud to have contributed to this creation of value by providing commercial and R&D support to the company over the course of our relationship, which will continue now with Eli Lilly, a well-respected research organization.
"From the beginning, we had viewed our potential acquisition of ImClone as a strategically and financially sound add-on to our oncology business, consolidating a successful relationship that has extended over seven years. We felt it was in the best interest of Bristol-Myers Squibb shareholders not to raise our previous $62/share all cash offer, exercising discipline and evaluating this potential investment within the context of other alternatives open to the company.
"Looking ahead, we will work closely with Eli Lilly and Company, a company I know well, to continue to bring to patients not only ERBITUX(R), the important cancer therapy we co-commercialize in the U.S. and Canada with ImClone, and co-develop in Japan with Merck KGaA and ImClone, but other compounds, including IMC-11F8, under development by ImClone to which Bristol-Myers Squibb holds long-term marketing rights."
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life.
SOURCE: Bristol-Myers Squibb
Bristol-Myers Squibb
Communications:
Tracy Furey,
Brian Henry,
or
Investor Relations:
John Elicker,
Copyright Business Wire 2008
BRISTOL-MYERS SQUIBB CO COM STK USD0.10
US1101221083
ELI LILLY AND COMPANY COM NPV
US5324571083
IMCLONE SYSTEMS INC COM USD0.001
US45245W1099